Pertussis Booster
Vaccines Forecast
Pertussis is a decades-old vaccine-preventable disease that just resurged sharply across the world in 2024, with Brazil's case count rising more than thirty-fold and France's more than tenfold in a matter of months. At the same time, ILiAD Biotechnologies' live-attenuated nasal candidate, BPZE1, became the first pertussis vaccine ever to demonstrate protection against colonization in a human challenge study, and is now moving toward Phase 3. This is the independent commercial assessment of what that resurgence and pipeline progress mean for the booster vaccine opportunity, drawing on VacZine Analytics' long-standing, independent authority in respiratory vaccine markets.
- Format
- PDF (~150 slides) + Excel (>50 sheets)
- Coverage
- 27 countries
- Vaccines assessed
- aP boosters, BPZE1, maternal Tdap
- Forecast horizon
- To 2030
- Approach
- Scenario-based
- Base edition
- December 2017
- Availability
- Syndicated / bespoke
in children under 5 (WHO)
in children under 5 (WHO)
2023 to 2024
pivotal Phase 3 human challenge trial
Why pertussis resurged, and why boosters matter again
Pertussis is one of vaccination's great long-term success stories, and also a cautionary tale about vaccine waning. Understanding both the decades-long decline in global burden and the sharp 2024 resurgence is central to understanding why booster strategy has become commercially and clinically urgent again.
Pathogen overview - Bordetella pertussis
Bordetella pertussis is a fastidious, Gram-negative bacterium that causes pertussis, or whooping cough, an acute respiratory disease found only in humans. Pertussis is characterised by paroxysmal coughing spasms and can be fatal, especially in unvaccinated infants and toddlers. WHO's widely cited 2014 estimate put global pertussis cases in children under 5 at 24.1 million, with approximately 160,700 deaths in that age group, 53% of them in infants under one year old. Pertussis remains one of the leading causes of vaccine-preventable death worldwide, despite generally high vaccination coverage.
Longer-term data tell a story of substantial progress: the Global Burden of Disease Study 2021 found that global pertussis cases fell by 77.7% and deaths by 80.3% between 1990 and 2021, with the heaviest remaining burden concentrated in low-resource settings and among infants. That progress made 2024's global resurgence all the more striking. Brazil's reported cases rose more than 34-fold, from 216 in 2023 to 7,438 in 2024, with 30 associated deaths, its first pertussis deaths since 2021. France identified more than 7,000 PCR-confirmed cases between January and May 2024 alone, versus roughly 500 for the whole of 2023. South Korea, the UK and the US all reported elevated case counts through 2024, prompting a July 2024 epidemiological alert from the Pan American Health Organization calling on countries to strengthen surveillance and vaccination monitoring.
The resurgence is widely attributed to vaccine waning and comparatively weaker, shorter-lived protection from newer acellular (aP) vaccines relative to older whole-cell (wP) formulations, compounded by rising macrolide antibiotic resistance now reported across Asia, Australia, Europe and South America. Data from newer preclinical models comparing aP and wP immune responses is prompting a broader rethink of pertussis vaccine design, even as most major manufacturers continue to focus, in the nearer term, on incremental adjustments to existing booster formulations. Maternal vaccination has become an important control strategy in many countries, though harmonisation with US recommendations in other target groups remains incomplete.
Against that backdrop, the most significant next-generation development is a change in vaccine platform rather than formulation. ILiAD Biotechnologies' BPZE1, a live-attenuated intranasal vaccine, has completed four Phase 2 studies and in 2023 became the first pertussis vaccine candidate to demonstrate protection against B. pertussis colonisation in a human challenge study. It received UK MHRA Innovation Passport designation in December 2024, and in January 2025 ILiAD signed a letter of intent with hVIVO for a pivotal Phase 3 human challenge trial, planned for the second half of 2025 following a Type C meeting with the FDA.
A platform-level rethink, arriving as boosters are needed more than ever
Most near-term competitor activity remains focused on incremental adjustments to existing acellular booster formulations. The more significant long-term shift is a live-attenuated nasal candidate that has already cleared a bar no acellular vaccine has: proof of protection against colonisation itself.
-
ILiAD BiotechnologiesHeading to Phase 3 (H2 2025)BPZE1 Live-attenuated, intranasal
The most advanced next-generation pertussis vaccine in clinical development, having completed four Phase 2 studies. In 2023 it became the first candidate to demonstrate protection against B. pertussis colonisation in a human challenge study. Received UK MHRA Innovation Passport designation in December 2024, and a pivotal Phase 3 human challenge trial with hVIVO is planned for the second half of 2025. -
Major manufacturersApproved, incremental focusExisting acellular (aP) boosters
Established infant, adolescent and adult booster products from major manufacturers remain the market's backbone. Near-term competitive activity is concentrated on incremental component adjustments rather than platform change. -
National immunisation programmesEstablished, uneven adoptionMaternal Tdap vaccination
Widely adopted as a control strategy to protect neonates in the highest-risk window, but recommendations for other target groups remain inconsistently harmonised with US guidance across markets. -
Academic & preclinical researchPreclinicalaP versus wP immunology research
Newer preclinical models comparing acellular and whole-cell immune responses are informing a longer-term rethink of pertussis vaccine design beyond the current acellular paradigm.
2024's global pertussis resurgence supplied real-world confirmation of the vaccine-waning thesis, just as BPZE1 became the first candidate to demonstrate protection against colonisation itself, a mechanism acellular vaccines have never achieved. Together, these two developments reframe the booster opportunity: not as a mature, slow-moving category, but as a market re-opening to platform-level differentiation. The VacZine Analytics model quantifies the commercial opportunity under multiple resurgence-severity and pipeline-progression scenarios.
Six analytical layers - one commercial picture
The MarketVIEW pertussis booster analysis spans disease burden, current vaccine and recommendation landscapes, the post-2024 competitor picture and scenario-based revenue forecasting across 27 countries to 2030.
Bottom-up modelling of pertussis booster vaccine volume and value across 27 countries to 2030, spanning infant, adolescent, adult and maternal target groups.
Existing acellular booster formulations, maternal Tdap programmes, and ILiAD's BPZE1 heading toward its pivotal Phase 3 human challenge trial.
Acellular versus whole-cell versus live-attenuated approaches, and the immunological rationale behind the current design rethink.
Volume (million doses) and value ($m) forecasts to 2030, with scenarios reflecting resurgence severity and next-generation pipeline timing.
Long-term GBD 2021 burden trends alongside country-level detail on the 2024/2025 global resurgence and rising macrolide resistance.
Current national recommendations, harmonisation gaps versus US guidance, and possible market entrance strategies for new entrants.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Vaccine type | Booster context | Revenue scenario |
|---|---|---|---|---|
| Adolescent booster cohort | 27-country model | Acellular (aP) | Routine schedule | Modelled |
| Adult booster cohort | 27-country model | Acellular (aP) | Waning protection | Modelled |
| Maternal vaccination (Tdap) | 27-country model | Acellular (aP) | Neonatal protection | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | 27-country model | All profiles | All contexts | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the pertussis booster vaccine opportunity.
- Executive presentation (~150 slides, PDF) - disease background, epidemiology, the 2024/2025 resurgence, competitor pipeline and full commercial assessment with supporting narrative and references
- MS-Excel forecast workbook (>50 worksheets) - volume (million doses) and value ($m) outputs across 27 countries to 2030, by relevant target group
- Scenario-based commercial forecasts - reflecting resurgence severity and next-generation pipeline progression, including BPZE1's path to Phase 3
- Competitor intelligence - existing acellular boosters, maternal Tdap programmes, and ILiAD Biotechnologies' BPZE1
- Updated epidemiology module - long-term GBD 2021 burden trends alongside 2024/2025 resurgence data and rising macrolide resistance
- Recommendation & market entry review - current national recommendations, harmonisation gaps, and possible market entrance strategies
Built for organisations weighing the pertussis booster opportunity
Most valuable to teams evaluating the pertussis booster vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of the 2024/2025 resurgence and BPZE1's advance toward Phase 3.
Vaccine developers
Positioning, commercial feasibility and target-population prioritisation for pertussis candidates at any stage.
Corporate strategy & BD
Validate the market size and structure following the 2024 resurgence, and understand what BPZE1's progress means for share.
Investors & analysts
Independent assessment of market size and pipeline risk for due diligence on pertussis and adjacent respiratory vaccine assets.
Public health & immunisation programmes
Demand modelling for booster, adolescent and maternal pertussis immunisation programmes.
Researchers & academia
Comprehensive epidemiology and vaccine landscape for grant and translational planning, including the aP/wP immunology debate.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public and private respiratory immunisation channels.
VacZine Analytics has tracked Respiratory vaccine markets since our earliest editions, positioning us to reassess the pertussis booster opportunity the moment the resurgence and pipeline both shifted. This analysis combines a rigorous epidemiological review with an independently constructed commercial model spanning 27 countries that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.
This December 2017 edition has been updated to incorporate the global 2024/2025 pertussis resurgence, GBD 2021 long-term burden trends, and ILiAD Biotechnologies' progress with BPZE1 toward its pivotal Phase 3 trial. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc pertussis analysis, a briefing call is included on request.